A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Mitapivat's pivotal win in a rare type of anaemia could bode well for its chances in thalassaemia and sickle cell disease.